Annexon, Inc. 4

Director Mark S. Blumenkranz received a stock option award for 175,000 shares of Annexon, Inc. common stock at a $5.39 exercise price on 2026-08-10.

On August 10, 2026, director Mark S. Blumenkranz was granted a stock option to purchase 175,000 shares of Annexon, Inc. common stock at an exercise price of $5.39 per share, with 1/36th of the option vesting monthly starting from August 10, 2026 and becoming fully vested on the third anniversary of that vesting commencement date, contingent on his continued service as a director. This is a routine equity compensation award rather than an open-market transaction, and following the grant he holds 175,000 derivative securities (options) corresponding to 175,000 underlying shares. Based on the exercise price as the best available proxy for value, the option grant represents an implied notional value of approximately $942,000 and establishes a meaningful, but standard, equity incentive alignment with shareholders.

Filing Facts

CIK

1528115

Ticker

ANNX

Form

4

Source Type

fda

Accession

0001614869-26-000004

Alert Tier

5